Research advances in pharmacological and toxicological activities of dioscin

doi:10.19803/j.1672-8629.2022.04.25

Abstract

Abstract: Dioscin is the principal active ingredient of a variety of herbs, natural drugs and listed traditional Chinese medicine preparations. It is used to treat cardiovascular diseases, arthritis and other diseases. In recent years, the anti-cancer activity of dioscin has been widely explored as a hotspot. This paper reviews the recent advances in pharmacological and toxicological studies on dioscin in order to facilitate research and development of dioscin.

Key words: dioscin, pharmacological activities, toxicological activities

CLC Number:

R994.1

FANG Cheng, XU Xiaomin, LIU Shumin. Research advances in pharmacological and toxicological activities of dioscin[J]. Chinese Journal of Pharmacovigilance, 2022, 19(4): 456-459.

References

[1] TAO XF, YIN LH, XU LN, et al.Dioscin: a diverse acting natural compound with therapeutic potential in metabolic diseases, cancer, inflammation and infections[J]. Pharmacological Research, 2018, 137: 259-269.
[2] ZHANG GX, ZENG XC, ZHANG R, et al.Dioscin suppresses hepatocellular carcinoma tumor growth by inducing apoptosis and regulation of TP53, BAX, BCL2 and cleaved CASP3[J]. Phytomedicine, 2016, 23(12): 1329-1336.
[3] YANG LF, REN SN, XU F, et al.Recent Advances in the pharm-acological activities of dioscin[J]. BioMed Research International, 2019, 2018(2): 13.
[4] YU YN, HU SY, LI GX, et al.Comparative effectiveness of Di'ao Xin Xue Kang capsule and compound Danshen tablet in patients with symptomatic chronic stable angina[J]. Scientific Reports, 2014(4): 7058.
[5] ZHOU WX, CHENG XR, ZHANG YX.Effect of Liuwei Dihuang decoction, a traditional Chinese medicinal prescription, on the neuroendocrine immunomodulation network[J]. Pharmacology & Therapeutics, 2016, 162(4): 170-178.
[6] GUO XQ, DING X.Dioscin suppresses the viability of ovarian cancer cells by regulating the VEGFR2 and PI3K/AKT/MAPK signaling pathways[J]. Oncology Letters, 2018, 15(6): 9537-9542.
[7] HWANG JT, PARK KS, RYUK JA, et al.Development of an oriental medicine discrimination method through analysis of steroidal saponins in dioscorea nipponica makino and their anti-osteosarcoma effects[J]. Molecules, 2019, 24(22): 4022.
[8] DING QY, ZHANG WD, CHENG C, et al.Dioscin inhibits the growth of human osteosarcoma by inducing G2/M-phase arrest, apoptosis, and GSDME-dependent cell death in vitro and in vivo[J]. Journal of Cellular Physiology, 2020, 235(3): 2911-2924.
[9] LI XJ, QU Z, JING SS, et al.Dioscin-6'-O-acetate inhibits lung cancer cell proliferation via inducing cell cycle arrest and caspase-dependent apoptosis[J]. Phytomedicine, 2019, 53: 124-133.
[10] MAO Z, HAN X, CHEN DH, et al.Potent effects of dioscin against hepatocellular carcinoma through regulating TP53-induced glycolysis and apoptosis regulator (TIGAR)-mediated apoptosis, autophagy, and DNA damage[J]. British Journal of Pharmacology, 2019, 176(7): 919-937.
[11] ZHANG YS, MA YL, THAKUR K, et al.Molecular mechanism and inhibitory targets of dioscin in HepG2 cells[J]. Food Chem Toxicol, 2018, 120: 143-154.
[12] CHAN SH, LIANG PH, GUH JH.An integrated approach to elucidate signaling pathways of dioscin-induced apoptosis, energy metabolism and differentiation in acute myeloid leukemia[J]. Naunyn-Schmiedeberg’s Archives of Pharmacology, 2018, 391(6): 587-602.
[13] ZHAO XR, YIN LH, FANG LL, et al.Protective effects of dioscin against systemic inflammatory response syndromevia adjusting TLR2/MyD88/NFkappab signal pathway[J]. Int Immunopharmacol, 2018, 65: 458-469.
[14] LI Y, LI Y, YANG T, et al.Dioscin attenuates oxLDL uptake and the inflammatory reaction of dendritic cells under high glucose conditions by blocking p38 MAPK[J]. Mol Med Rep, 2020, 21(1): 304-310.
[15] DU ST, LI C, LU YP, et al.Dioscin alleviates crystalline silica-induced pulmonary inflammation and fibrosis through promoting alveolar macrophage autophagy[J]. Theranostics, 2019, 9(7): 1878-1892.
[16] WU ZL, WANG J.Dioscin attenuates bleomycin-induced acute lung injury via inhibiting the inflammatory response in mice[J]. Experimental Lung Research, 2019, 45(8): 236-244.
[17] CAO YJ, XU Y, LIU B, et al.Dioscin, a steroidal saponin isolated from dioscorea nipponica, attenuates collagen-induced arthritis by inhibiting Th17 cell response[J]. The American Journal of Chinese Medicine, 2019, 47(2): 423-37.
[18] YANG LF, LIU X, ZHONG LL, et al.Dioscin inhibits virulence factors of candida albicans[J]. Biomed Research International, 2018, 26: 4651726.
[19] CAI SY, CHEN JX, LI YS.Dioscin protects against diabetic nephropathy by inhibiting renal inflammation through TLR4/NF-κB pathway in mice[J]. Immunobiology, 2020, 225(3): 151941.
[20] YANG B, XU B, ZHAO H, et al.Dioscin protects against coronary heart disease by reducing oxidative stress and inflammation via Sirt1/Nrf2 and p38 MAPK pathways[J]. Molecular Medicine Reports, 2018, 18(1): 973-980.
[21] CHENG J, SUN C, ZHANG JY, et al.The protective effects of preconditioning with dioscin on myocardial ischemia/reperfusion-induced ventricular arrhythmias by increasing connexin 43 expression in rats[J]. Journal of Cardiovascular Pharmacology and Therapeutics, 2019, 24(3): 262-268.
[22] CHEN L, LI QN, LEI L, et al.Dioscin ameliorates cardiac hypertrophy through inhibition of the MAPK and Akt/GSK3beta/mTOR pathways[J]. Life Sciences, 2018, 209(15): 420-429.
[23] FAN TF, HE JH, YIN YQ, et al.Dioscin inhibits intimal hyperplasia in rat carotid artery balloon injury model through inhibition of the MAPK-FoxM1 pathway[J]. European Journal of Pharmacology, 2019, 854(5): 213-223.
[24] YAO H, TAO XF, XU LN, et al.Dioscin alleviates non-alcoholic fatty liver disease through adjusting lipid metabolism via SIRT1/AMPK signaling pathway[J]. Pharmacological Research, 2018, 131: 51-60.
[25] SONG SS, CHU L, LIANG HF, et al.Protective effects of dioscin against doxorubicin-induced hepatotoxicity via regulation of sirt1/foxo1/nf-kappab signal[J]. Front Pharmacol, 2019, 10: 1030.
[26] HU YP, MAO Z, XU LN, et al.Protective effect of dioscin against intestinal ischemia/reperfusion injury via adjusting miR-351-5p-mediated oxidative stress[J]. Pharmacol Res, 2018, 137: 56-63.
[27] ZHENG LL, HAN X, HU YP, et al.Dioscin ameliorates intestinal ischemia/reperfusion injury via adjusting miR-351-5p/MAPK13-mediated inflammation and apoptosis[J]. Pharmacol Res, 2019, 139: 431-439.
[28] QI Y, LI RM, XU LN, et al.Neuroprotective effect of dioscin on the aging brain[J]. Molecules, 2019, 24(7): 1247.
[29] WANG CT, LI QN, LI TY.Dioscin alleviates lipopolysaccharide-induced acute lung injury through suppression of TLR4 signaling pathways[J]. Exp Lung Res, 2020, 46(1-2): 11-22.
[30] XU TT, ZHANG S, ZHENG LL, et al.A 90-day subchronic toxicological assessment of dioscin, a natural steroid saponin, in Sprague-Dawley rats[J]. Food and Chemical Toxicology, 2012, 50(5): 1279-1287.
[31] GUO YC, AN G, ZHAO XF, et al.Subchronic toxicological assessment of diosgenin in kunming mice[J]. Modernization of Traditi-onal Chinese Medicine and Materia Medica-World Science and Technology(世界科学技术-中医药现代化), 2015, 17(9): 1823-1827.
[32] LIN LF, YUAN F, LIU YL, et al.Hepatotoxicity and mechanism study of chrysophanol-8-O-glucoside in vitro[J]. Biomed Pharmac-other, 2019, 120: 109531.
[33] ZHOU Q, YAO GT, JIN RM.The hepatotoxicity of diosgenin[J]. Chinese Journal of Pharmacology and Toxicology(中国药理学与毒理学杂志), 2013, 27(3): 550-551.
[34] ZHANG YX, WANG YG, MA ZC, et al.Preliminary study on hepatotoxicity induced by dioscin and its possible mechanism[J]. China Journal of Chinese Materia Medica(中国中药杂志), 2015, 40(14): 2748-2752.
[35] ZHOU Y, LU YL, CHE WX.Two cases of liver damage were caused by Di’ao Xinuankang[J]. Chinese Pharmaceutical Affairs(中国药事), 1999(2): 60-61.
[36] LEI ZB.Analysis of adverse reactions of Di’ao Xinuekang capsule[J]. Chinese Traditional Patent Medicine(中成药), 2011, 33(6): 1037-1039.
[37] WANG GP, WANG YL, SUN YB, et al.Clinical analysis of 6 cases of liver function damage caused by diosgenin tablets[J]. Chinese Remedies & Clinics(中国药物与临床), 2011, 11(2): 190-191.
[38] LI A, ZHANG B.Survey and consideration on safety status of traditional Chinese medicine application in 685 primary healthcare workers[J]. Chinese Journal of Pharmacovigilance(中国药物警戒), 2018, 15(12): 721-727.